2. Metabolic Enzyme/Protease
  3. Isocitrate Dehydrogenase (IDH)
  4. Ivosidenib

Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1448347-49-6

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 103 在庫あり
Solution
10 mM * 1 mL in DMSO USD 103 在庫あり
Solid
5 mg $80 在庫あり
10 mg $147 在庫あり
25 mg $240 在庫あり
50 mg $384 在庫あり
100 mg $624 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 19 publication(s) in Google Scholar

Other Forms of Ivosidenib:

Ivosidenib 関連抗体

Top Publications Citing Use of Products

    Ivosidenib purchased from MedChemExpress. Usage Cited in: Cancer Drug Resist. 2025 Apr 24:8:20.  [Abstract]

    Dose-response curves of SKOV3, CAOV3, and OVCAR4 detected by MTT assay treated with cisplatin and 0 μM, 1 μM, 5 μM, 10 μM, 20 μM, and 50 μM Ivosidenib for 72 h.

    Ivosidenib purchased from MedChemExpress. Usage Cited in: Cancer Drug Resist. 2025 Apr 24:8:20.  [Abstract]

    Quantification of cell colony number in SKOV3, CAOV3, and OVCAR4 cells treated with Ivosidenib (10 μM), Cisplatin, or their combination.

    Ivosidenib purchased from MedChemExpress. Usage Cited in: J Med Chem. 2023 Apr 13;66(7):5279-5288.  [Abstract]

    Ivosidenib is the most potent IDH1 R132H inhibitor, exhibiting similar binding affinities to wild-type IDH1 and IDH1 R132H, with KD values of 416 nM and 488 nM, respectively.

    Ivosidenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Aug 15;13(1):4785.  [Abstract]

    Inhibition (%) of IDH1 variants (400 nM) by Ivosidenib (10 µM) as determined by the NADPH absorbance assay. Errors: standard errors of the mean (n = 3 independent replicates measured on the same 96-well plate).

    Ivosidenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Aug 15;13(1):4785.  [Abstract]

    Non-denaturing MS analysis measuring binding of Ivosidenib to IDH1 variants. At 20 µM IDH1 variants are predominantly dimeric with 2 NADP(H) molecules bound-dashed line. Green background corresponds to binding of one Ivosidenib molecule. Final concentrations of Ivosidenib: 5 µM (4:1), 20 µM (1:1), and 160 µM (1:8). Cone-voltage: 100 V.

    Ivosidenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Aug 15;13(1):4785.  [Abstract]

    LN18 cells were treated with the inhibitors Ivosidenib (24 h), GSK864, FT-2102, IDH224, and DS-1001B in DMSO (final concentration: 5 µM). 2-HG levels were determined by anion-exchange chromatography coupled to MS51 (errors: standard errors of the mean, n = 4 independent replicates).

    Isocitrate Dehydrogenase (IDH) アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    IDH1 IDH2

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity[1].

    IC50 & Target

    IDH1

     

    Cellular Effect
    Cell Line Type Value Description References
    HT-1080 IC50
    8 nM
    Compound: 99; AG-120
    Antiproliferative activity against human HT-1080 cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HT-1080 cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 37235998]
    HT-1080 IC50
    8 nM
    Compound: 99; AG-120
    Antiproliferative activity against human HT-1080 cells harboring IDH1 R132H mutant measured after 72 hrs by MTT assay
    Antiproliferative activity against human HT-1080 cells harboring IDH1 R132H mutant measured after 72 hrs by MTT assay
    		[PMID: 37235998]
    U-87MG ATCC IC50
    0.56 μM
    Compound: 2; AG-120
    Synergistic antiproliferative activity against human U-87 MG cells harboring IDH1 R132H mutant assessed as inhibition of cell growth incubated for 48 hrs in presence of FK866 by CCK8 assay
    Synergistic antiproliferative activity against human U-87 MG cells harboring IDH1 R132H mutant assessed as inhibition of cell growth incubated for 48 hrs in presence of FK866 by CCK8 assay
    		[PMID: 38651495]
    U-87MG ATCC IC50
    0.98 μM
    Compound: 2; AG-120
    Antiproliferative activity against human U-87 MG cells harboring IDH1 R132H mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human U-87 MG cells harboring IDH1 R132H mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    		[PMID: 38651495]
    U-87MG ATCC IC50
    1.02 μM
    Compound: 2; AG-120
    Antiproliferative activity against human U-87 MG cells harboring IDH1 R132H mutant assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human U-87 MG cells harboring IDH1 R132H mutant assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 38651495]
    U-87MG ATCC IC50
    100.06 μM
    Compound: 2; AG-120
    Antiproliferative activity against human U-87 MG cells harboring wildtype IDH1 assessed as inhibition of cell growth incubated for 24 hrs by CCK8 assay
    Antiproliferative activity against human U-87 MG cells harboring wildtype IDH1 assessed as inhibition of cell growth incubated for 24 hrs by CCK8 assay
    		[PMID: 38651495]
    U-87MG ATCC IC50
    19 nM
    Compound: 99; AG-120
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth by CCK-8 assay
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth by CCK-8 assay
    		[PMID: 37235998]
    U-87MG ATCC IC50
    19 nM
    Compound: 99; AG-120
    Antiproliferative activity against human U-87 MG cells harboring IDH1 R132H mutant measured after 72 hrs by MTT assay
    Antiproliferative activity against human U-87 MG cells harboring IDH1 R132H mutant measured after 72 hrs by MTT assay
    		[PMID: 37235998]
    U-87MG ATCC IC50
    2.51 μM
    Compound: 2; AG-120
    Synergistic antiproliferative activity against human U-87 MG cells harboring wildtype IDH1 assessed as inhibition of cell growth incubated for 48 hrs in presence of FK866 by CCK8 assay
    Synergistic antiproliferative activity against human U-87 MG cells harboring wildtype IDH1 assessed as inhibition of cell growth incubated for 48 hrs in presence of FK866 by CCK8 assay
    		[PMID: 38651495]
    U-87MG ATCC IC50
    3.06 μM
    Compound: 2; AG-120
    Antiproliferative activity against human U-87 MG cells harboring IDH1 R132H mutant assessed as inhibition of cell growth incubated for 24 hrs by CCK8 assay
    Antiproliferative activity against human U-87 MG cells harboring IDH1 R132H mutant assessed as inhibition of cell growth incubated for 24 hrs by CCK8 assay
    		[PMID: 38651495]
    U-87MG ATCC IC50
    67.22 μM
    Compound: 2; AG-120
    Antiproliferative activity against human U-87 MG cells harboring wildtype IDH1 assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human U-87 MG cells harboring wildtype IDH1 assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    		[PMID: 38651495]
    U-87MG ATCC IC50
    89.34 μM
    Compound: 2; AG-120
    Antiproliferative activity against human U-87 MG cells harboring wildtype IDH1 assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human U-87 MG cells harboring wildtype IDH1 assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 38651495]
    体外実験

    Ivosidenib (AG-120) (0-13 μM; 48 hours) inhibits several IDH1-R132 mutants with potency similar IC50 values: IDH1-R132H (IC50=12 nM); IDH1-R132C (IC50=13 nM); IDH1-R132G (IC50=8 nM); IDH1-R132L (IC50=13 nM); IDH1-R132S (IC50=12 nM), respectively[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ivosidenib 関連抗体
    体内実験

    AG-120 (gavage administration; 50 mg/kg and 150 mg/kg) declines tumor 2-HG concentration rapidly, with maximum inhibition (92.0% and 95.2% at the 50 mg/kg and 150 mg/kg doses, respectively) achieved at -12 h post dose[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female nude BALB/c mice inoculated with HT1080 cells[1]
    Dosage: 50 mg/kg and 150 mg/kg
    Administration: Gavage administration; 50 mg/kg and 150 mg/kg
    Result: Showed robust tumor 2-HG reduction in mouse.
    臨床実験
    分子量

    582.96

    分子式

    C28H22ClF3N6O3
    CAS 番号
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    ClC1=C([C@H](N(C2=CC(F)=CN=C2)C([C@H]3N(C4=NC=CC(C#N)=C4)C(CC3)=O)=O)C(NC5CC(F)(F)C5)=O)C=CC=C1
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 100 mg/mL (171.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.7154 mL 8.5769 mL 17.1538 mL
    5 mM 0.3431 mL 1.7154 mL 3.4308 mL
    10 mM 0.1715 mL 0.8577 mL 1.7154 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 5 mg/mL (8.58 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.89%

    COA (258 KB) HNMR (138 KB) RP-HPLC (225 KB) LCMS (94 KB)

    取扱説明書 (2659 KB)
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.7154 mL 8.5769 mL 17.1538 mL 42.8846 mL
    5 mM 0.3431 mL 1.7154 mL 3.4308 mL 8.5769 mL
    10 mM 0.1715 mL 0.8577 mL 1.7154 mL 4.2885 mL
    15 mM 0.1144 mL 0.5718 mL 1.1436 mL 2.8590 mL
    20 mM 0.0858 mL 0.4288 mL 0.8577 mL 2.1442 mL
    25 mM 0.0686 mL 0.3431 mL 0.6862 mL 1.7154 mL
    30 mM 0.0572 mL 0.2859 mL 0.5718 mL 1.4295 mL
    40 mM 0.0429 mL 0.2144 mL 0.4288 mL 1.0721 mL
    50 mM 0.0343 mL 0.1715 mL 0.3431 mL 0.8577 mL
    60 mM 0.0286 mL 0.1429 mL 0.2859 mL 0.7147 mL
    80 mM 0.0214 mL 0.1072 mL 0.2144 mL 0.5361 mL
    100 mM 0.0172 mL 0.0858 mL 0.1715 mL 0.4288 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ivosidenib Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ivosidenib1448347-49-6AG-120AG120AG 120Isocitrate Dehydrogenase (IDH)Inhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Ivosidenib
    製品番号:
    HY-18767
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.